Skip to search formSkip to main contentSkip to account menu

NKTR-214

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Interleukin-2Polyethylene Glycols
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
2623 Background: PIVOT-02 is an ongoing phase 1/2 study of bempegaldesleukin (NKTR-214), a CD122-preferential IL-2 pathway… 
2019
2019
Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors…
26 Background: NKTR-262 is a novel intratumoral prodrug designed to promote tumor antigen release, an immune stimulatory… 
2019
2019
A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal…
TPS4595 Background: Bempegaldesleukin (NKTR-214) is a CD122-preferential IL-2 pathway agonist that stimulates proliferation and… 
Review
2019
Review
2019
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or…
TPS9601 Background: Standard of care for pts with previously untreated, unresectable or metastatic MEL includes checkpoint… 
2019
2019
Pilot study of NKTR214 and nivolumab in patients with sarcomas.
11010 Background: Monotherapy checkpoint inhibitors have minimal efficacy in most patients with metastatic sarcoma. NKTR-214 is a… 
2018
2018
Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214
Background: NKTR-262 is a novel therapeutic, which delivers intratumoral engagement of the TLR 7/8 pathway, promoting an immune… 
2018
2018
Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.
3085Background: BXCL701 targets DPP8/9 and stimulates migration and cytotoxicity of T and NK cells in addition to targeting… 
2017
2017
Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma.
454Background: Patients with low baseline CD8+ T-cells within the tumor microenvironment (TILs) have a poor response to immune… 
2016
2016
Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade
Background: While immune checkpoint blockade is a promising therapeutic approach, combination with agents that modulate… 
2016
2016
Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor.
11545Background: NKTR-214 is an immune-stimulatory cytokine designed to provide a controlled, sustained, and CD122-biased… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)